Comparison of binding characterization of two antiviral drugs to human serum albumin

Chemical Biology and Drug Design

Volumn 83, Issue 5, 2014, Pages 576-582

  Li, Mei ^a   McAuley, Erin ^b   Zhang, Yao ^a   Kong, Linlin ^a   Yang, Feng ^a   Zhou, Zuping ^a   Wu, Xiaoyang ^b   Liang, Hong ^a  

^a GUANGXI NORMAL UNIVERSITY   (China)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

antiviral drug; fluorescence spectroscopy; human serum albumin; protein drug interaction; X ray crystallography

Indexed keywords

HUMAN SERUM ALBUMIN; INDOMETACIN; LAMIVUDINE; RIBAVIRIN; ZIDOVUDINE; ANTIVIRUS AGENT; PROTEIN BINDING; SERUM ALBUMIN;

ARTICLE; BINDING AFFINITY; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DRUG MECHANISM; DRUG PROTEIN BINDING; FLAME PHOTOMETRY; FLUORESCENCE SPECTROSCOPY; HYDROGEN BOND; PRIORITY JOURNAL; X RAY CRYSTALLOGRAPHY; X RAY DIFFRACTION; BINDING SITE; CHEMISTRY; HUMAN; METABOLISM; MOLECULAR DYNAMICS; PROTEIN TERTIARY STRUCTURE;

ANTIVIRAL AGENTS; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; HUMANS; HYDROGEN BONDING; LAMIVUDINE; MOLECULAR DYNAMICS SIMULATION; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RIBAVIRIN; SERUM ALBUMIN;

EID: 84899492176     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/cbdd.12270     Document Type: Article

References (34)

1. Peters T., (1995) All About Albumin: Biochemistry, Genetics, and Medical Applications. San Diego, CA: Academic Press.
2. Yamasaki K., Chuang V.T., Maruyama T., Otagiri M., (2013) Albumin-drug interaction and its clinical implication. Biochim Biophys Acta; 1830: 5435-5443.
3. Fasano M., Curry S., Terreno E., Galliano M., Fanali G., Narciso P., Notari S., Ascenzi P., (2005) The extraordinary ligand binding properties of human serum albumin. IUBMB Life; 57: 787-796. (Pubitemid 43062399)
4. Stewart A.J., Blindauer C.A., Berezenko S., Sleep D., Sadler P.J., (2003) Interdomain zinc site on human albumin. Proc Natl Acad Sci U S A; 100: 3701-3706. (Pubitemid 36418095)
5. Bal W., Sokołowska M., Kurowska E., Faller P., (2013) Binding of transition metal ions to albumin: sites, affinities and rates. Biochim Biophys Acta; 1830: 5444-5455.
6. Ghuman J., Zunszain P.A., Petitpas I., Bhattacharya A.A., Otagiri M., Curry S., (2005) Structural basis of the drug-binding specificity of human serum albumin. J Mol Biol; 353: 38-52. (Pubitemid 41338838)
7. Fanali G., di Masi A., Trezza V., Marino M., Fasano M., Ascenzi P., (2012) Human serum albumin: from bench to bedside. Mol Aspects Med; 33: 209-290.
8. Simard J.R., Zunszain P.A., Ha C.E., Yang J.S., Bhagavan N.V., Petitpas I., Curry S., Hamilton J.A., (2005) Locating high-affinity fatty acid-binding sites on albumin by x-ray crystallography and NMR spectroscopy. Proc Natl Acad Sci U S A; 102: 17958-17963. (Pubitemid 41798484)
9. He X.M., Carter D.C., (1992) Atomic structure and chemistry of human serum albumin. Nature; 358: 209-215.
10. Sudlow G., Birkett D.J., Wade D.N., (1975) The characterization of two specific drug binding sites on human serum albumin. Mol Pharmacol; 11: 824-832.
11. Yamaguchi S., Aldini G., Ito S., Morishita N., Shibata T., Vistoli G., Carini M., Uchida K., (2010) Delta12-prostaglandin J2 as a product and ligand of human serum albumin: formation of an unusual covalent adduct at His146. J Am Chem Soc; 132: 824-832.
12. Curry S., (2009) Lessons from the crystallographic analysis of small molecule binding to Human serum albumin. Drug Metab Pharmacokinet; 24: 342-357.
13. Wang Z.M., Ho J.X., Ruble J.R., Rose J., Rüker F., Ellenburg M., Murphy R., Click J., Soistman E., Wilkerson L., Carter D.C., (2013) Structural studies of several clinically important oncology drugs in complex with human serum albumin. Biochim Biophys Acta; 1830: 5356-5374.
14. Zunszain P.A., Ghuman J., McDonagh A.F., Curry S., (2008) Crystallographic analysis of human serum albumin complexed with 4Z,15E-bilirubin-IXalpha. J Mol Biol; 381: 394-406.
15. Craparo E.F., Teresi G., Licciardi M., Bondí M.L., Cavallaro G., (2013) Novel composed galactosylated nanodevices containing a ribavirin prodrug as hepatic cell-targeted carriers for HCV treatment. J Biomed Nanotechnol; 9: 1107-1122.
16. Pan C.Q., Lee H.M., (2013) Antiviral therapy for chronic hepatitis B in pregnancy. Semin Liver Dis; 33: 138-146.
17. Virovic L., Wu C.H., Konishi M., Wu G.Y., (2005) Novel delivery methods for treatment of viral hepatitis: an update. Expert Opin Drug Deliv; 2: 707-717. (Pubitemid 41038681)
18. Elsadek B., Kratz F., (2012) Impact of albumin on drug delivery-New applications on the horizon. J Control Release; 157: 4-28.
19. Kratz F., Elsadek B., (2012) Clinical impact of serum proteins on drug delivery. J Control Release; 161: 429-445.
20. Kratz F., (2008) Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release; 132: 171-183.
21. Neumann E., Frei E., Funk D., Becker M.D., Schrenk H.H., Müller-Ladner U., Fiehn C., (2010) Native albumin for targeted drug delivery. Expert Opin Drug Deliv; 7: 915-925.
22. Curry S., Mandelkow H., Brick P., Franks N., (1998) Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding sites. Nat Struct Biol; 5: 827-835. (Pubitemid 28402087)
23. DeLano W.L., (2004) The PyMol Molecular Graphics System. San Carlos, CA: DeLano ScientiWc.
24. Chatterjee T., Pal A., Dey S., Chatterjee B.K., (2012) Chakrabarti P.Interaction of virstatin with human serum albumin: spectroscopic analysis and molecular modeling. PLoS ONE; 7: e38372.
25. Kang J., Liu Y., Xie M.X., Li S., Jiang M., Wang Y.D., (2004) Interactions of human serum albumin with chlorogenic acid and ferulic acid. Biochim Biophys Acta; 1674: 205-214. (Pubitemid 40125392)
26. Gokara M., Sudhamalla B., Amooru D.G., Subramanyam R., (2010) Molecular interaction studies of trimethoxy flavone with human serum albumin. PLoS ONE; 1: 8834-8842.
27. Abou-Zied O.K., AlShihi O.I., (2008) Characterization of subdomain IIA binding site of human serum albumin in its native, unfolded, and refolded states using small molecular probes. J Am Chem Soc; 130: 10793-10801.
28. Bhattacharya A.A., Grune T., Curry S., (2000) Crystallographic analysis reveals common modes of binding of medium and long-chain fatty acids to human serum albumin. J Mol Biol; 303: 721-732.
29. Belatik A., Hotchandani S., Carpentier R., Tajmir-Riahi H.A., (2012) Locating the binding sites of Pb(II) ion with human and bovine serum albumins. PLoS ONE; 7: e36723.
30. Xie X., Lü W., Chen X., (2013) Binding of the endocrine disruptors 4-tert-octylphenol and 4-nonylphenol to human serum albumin. J Hazard Mater; 248-249: 347-354.
31. Yang F., Bian C., Zhu L., Zhao G., Huang Z., Huang M., (2007) Effect of human serum albumin on drug metabolism: structural evidence of esterase activity of human serum albumin. J Struct Biol; 157: 348-355. (Pubitemid 46109335)
32. Vorum H., Honore B., (1996) Influence of fatty acids on the binding of warfarin and phenprocoumon to human serum albumin with relation to anticoagulant therapy. J Pharm Pharmacol; 48: 870-875. (Pubitemid 26335272)
33. Zhu L., Yang F., Chen L., Meehan E.J., Huang M., (2008) A new drug binding subsite on human serum albumin and drug-drug interaction studied by X-ray crystallography. J Struct Biol; 162: 40-49.
34. Yang F., Yue J., Ma L., Ma Z., Li M., Wu X., Liang H., (2012) Interactive associations of drug-drug and drug-drug-drug with IIA subdomain of human serum albumin. Mol Pharm; 9: 3259-3265.